ABCcolla Bone Graft

K171629 · Acro Biomedical Co., Ltd. · MQV · Feb 1, 2018 · Orthopedic

Device Facts

• Record ID: K171629
• Device Name: ABCcolla Bone Graft
• Applicant: Acro Biomedical Co., Ltd.
• Product Code: MQV · Orthopedic
• Decision Date: Feb 1, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3045
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

ABCcolla® Bone Graft is an implant intended to fill bony voids or gaps of the skeletal system (i.e., extremities and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. ABCcolla® Bone Graft resorbs and is replaced with bone during the healing process.

Device Story

ABCcolla® Bone Graft is a porcine-derived bone mineral matrix; functions as a resorbable bone void filler. Implanted by surgeons into skeletal voids or gaps (extremities/pelvis) not requiring structural stability. Device resorbs over time, facilitating replacement with natural bone during healing. Supplied in granule and cube shapes; sterilized via gamma-irradiation. Intended for single-use clinical application.

Clinical Evidence

No human clinical data. Evidence includes bench testing: chemical composition (XRD, ICP/MS), morphology/pore size (SEM), porosity (mercury intrusion), density, and moisture content. Biocompatibility testing per ISO 10993 series (parts 1, 3, 4, 5, 6, 10, 11). Sterilization validated per ISO 11137. Shelf-life evaluated via real-time aging. Pyrogenicity assessed via LAL method. Pre-clinical animal performance testing conducted using a critical-size bone defect model to evaluate new bone formation.

Technological Characteristics

Porcine-derived bone mineral matrix; hydroxyapatite composition. Supplied as granules or cubes. Sterilized via gamma-irradiation (ISO 11137). Characterized by Ca/P ratio, pore size, and porosity. Non-software device.

Indications for Use

Indicated for patients requiring filling of bony voids or gaps in the skeletal system (extremities and pelvis) that are not intrinsic to the stability of the bony structure, resulting from surgical creation or traumatic injury.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Predicate Devices

• ORTHOSS® Resorbable Bone Void Filler (K090401)
• Bicera™ Resorbable Bone Substitute (K110949)

Reference Devices

• Geistlich Bio-Oss® (K122894)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logos of the Department of Health and Human Services and the Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.

February 1, 2018

ACRO Biomedical Co., Ltd. Dar-Jen Hsieh Chief Executive Officer 3F, No. 57, Luke 2nd Road, Lujhu District Kaohsiung City 82151 TAIWAN

Re: K171629

Trade/Device Name: ABCcolla® Bone Graft Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MOV Dated: January 10, 2018 Received: January 10, 2018

Dear Dar-Jen Hsieh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good

{1}------------------------------------------------

manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

## Katherine D. Kavlock -S

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for ACRO Biomedical Co., Ltd. The logo consists of a plus sign made up of a gray square on the top left, a red square on the bottom left, and a green leaf on the top right. To the right of the plus sign is the text "ACRO Biomedical Co., Ltd." in gray.

## Indications for Use Statement

510(K) Number (If Known): __K171629

Device Name: ABCcolla® Bone Graft

Indications for Use: ABCcolla® Bone Graft is an implant intended to fill bony voids or gaps of the skeletal system (i.e., extremities and These osseous defects are surgically created or the pelvis). result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. ABCcolla® Bone Graft resorbs and is replaced with bone during the healing process.

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH Office of Device Evaluation (ODE)

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image features the logo of ACRO Biomedical Co., Ltd. The logo consists of a stylized medical cross in gray and red, with a green leaf element incorporated into the design. The text "ACRO Biomedical Co., Ltd." is positioned to the right of the cross, with the company name underlined.

## 510(k) Summary

This summary of 510(k) Safety and Effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act (SMDA) of 1990 and Title 21 CFR 807.92. The assigned 510(k) number is_________________________________________________________________________________________________________________________________________________

| Applicant | ACRO Biomedical Co., Ltd. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 3rd Fl., No.57, Luke 2nd Rd., Lujhu Dist., Kaohsiung City 82151 |
| | Taiwan |
| | Telephone: [phone] |
| | Fax: [phone] |
| Contact Person | DAR-JEN HSIEH |
| | CEO |
| | E mail: [e-mail] |
| Date of Summary | May 1st, 2017 |
| Name of Device | ABCcolla® Bone Graft |
| Common Name | Resorbable Bone Void Filler |
| Classification | Class II |
| Regulation Number | 21 CFR 888.3045 |
| Product Code | MQV |
| Advisory Panel | ORTHOPEDIC DEVICES |
| Predicate Device | • ORTHOSS® Resorbable Bone Void Filler, K090401<br>Ed. Geistlich Soehne Ag Für Chemische Industrie<br>• Bicera™ Resorbable Bone Substitute, K110949<br>Wiltrom Corporation Limited |
| Reference Device | · Geistlich Bio-Oss®, K122894<br>Geistlich Pharma Ag |
| Device Description | ABCcolla® Bone Graft is a bone mineral matrix of porcine origin.<br>ABCcolla® Bone Graft is physically and chemically comparable to<br>the mineralized matrix of human bone. |
| Intended Use | ABCcolla® Bone Graft is an implant intended to fill bony voids or<br>gaps of the skeletal system (i.e., extremities and pelvis). These<br>osseous defects are surgically created or the result of traumatic<br>injury to the bone and are not intrinsic to the stability of the bony<br>structure. ABCcolla® Bone Graft resorbs and is replaced with bone<br>during the healing process. |
| Technological | ABCcolla® Bone Graft has been designed and manufactured to be |

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for ACRO Biomedical Co., Ltd. The logo consists of a stylized cross in gray and red with a green leaf on the top right corner. To the right of the cross is the text "ACRO Biomedical Co., Ltd." in gray, with a line underneath each word.

Characteristics substantially equivalent to predicate and reference device through comparison in areas including intended use, material origin, physical structure, chemical characteristics (hydroxyapatite, Ca/P ratio), principles of operation and design (user, how supplied, single use, gamma-irradiation sterilization).

ABCcolla® Bone Graft was designed in granule and cube shape similar to the predicate and reference device with different particle size which is between in the maximum and minimum size of the predicate device.

The performance of ABCcolla® Bone Graft, including chemical Performance Data composition, physical properties, biocompatibility, sterilization, packing, shelf-life, pyrogenicity and pre-clinical animal performance testing were performed to demonstrate substantial equivalence to the predicate devices.

> Chemical composition (hydroxyapatite, Ca/P ratio) was analyzed via X-ray diffraction (XRD), trace element analysis was performed by inductively coupled plasma/mass spectroscopy (ICP/ MS), particle pore size and morphology was evaluated via scanning

{5}------------------------------------------------

electron microscopy (SEM), porosity was determined by mercury intrusion porosimetry, density was evaluated via tap density analyzer, and moisture content was determined by moisture analyzer.

Biocompatibility studies were performed in accordance with ISO 10993-1, ISO10993-3, ISO10993-4, ISO 10993-5, ISO 10993-6, ISO 10993-10 and ISO10993-11. ABCcolla® Bone Graft was sterilized by gamma-irradiation and the process was validated in accordance with ISO 11137. ABCcolla® Bone Graft also has been tested for its packing integrity. The product shelf-life was evaluated in real-time aging study with passing results. Pyrogenicity was assessed with limulus amebocyte lysate (LAL) method and met the limits of established guidelines.

According to Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device, critical-size bone defect model was performed to evaluated the new bone formation and healing effect of ABCcolla® Bone Graft in pre-clinical animal performance testing.

Substantial ABCcolla® Bone Graft is substantially equivalent to the predicate Equivalence device with respect to functionality, design, materials, sterilized Summary method, package material, intended use and performance characteristics.

Conclusion Based on the 510(k) summaries and the information provided herein, we conclude that ABCcolla® Bone Graft is substantially equivalent to the predicate device under the Federal Food, Drug, and Cosmetic Act.